Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT)
- 18 December 2009
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 12 (1), 75-81
- https://doi.org/10.1093/eurjhf/hfp154
Abstract
Elevated heart rate is a significant marker for mortality and morbidity in cardiovascular disease including heart failure. Despite background treatment with a beta-blocker, many patients with heart failure and low ejection fraction maintain a heart rate above 70 b.p.m. Ivabradine reduces heart rate directly through inhibition of the I(f) ionic current. Methods SHIFT is a randomized, double-blind study designed to compare ivabradine with placebo on outcomes in patients with symptomatic chronic heart failure (NYHA class II-IV), left-ventricular ejection fraction < or =35%, and a prior hospitalization for worsening heart failure within the previous 12 months. Randomized treatment is given on top of guidelines-based therapy for chronic heart failure, including a beta-blocker at optimized dose. Resting heart rate at baseline must be > or =70 b.p.m. The primary endpoint is the composite of the time to first event of cardiovascular death or hospitalization for worsening heart failure. Secondary endpoints include all-cause, cardiovascular and heart failure mortality, and hospitalization. The randomized treatment period lasts approximately 12-48 months. The study will include approximately 6500 patients and will continue until > or =1600 primary endpoints have occurred. The first patient was randomized in October 2006, and the study is expected to end in 2010. The SHIFT study will assess if a heart rate reduction by direct sinus node inhibition can reduce cardiovascular outcomes in patients with chronic heart failure and left-ventricular systolic dysfunction.Keywords
This publication has 34 references indexed in Scilit:
- Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003Circulation, 2009
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008‡European Journal of Heart Failure, 2008
- Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trialThe Lancet, 2008
- Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge RegistryEuropean Heart Journal, 2008
- Resting Heart Rate in Cardiovascular DiseaseJournal of the American College of Cardiology, 2007
- Funny channels in the control of cardiac rhythm and mode of action of selective blockersPharmacological Research, 2006
- Predictors of mortality and morbidity in patients with chronic heart failureEuropean Heart Journal, 2005
- Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery diseaseEuropean Heart Journal, 2005
- Decreasing one-year mortality and hospitalization rates for heart failure in Sweden Data from the Swedish Hospital Discharge Registry 1988 to 2000Published by Oxford University Press (OUP) ,2004
- β-Blockers in Chronic Heart FailureCirculation, 2003